Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.60 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 3/20 | 0.45 |
| ▸ | RAB9A | P51151 | 3/20 | 0.45 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.44 |
| ▸ | MAPT | P10636 | 3/20 | 0.43 |
| ▸ | TTR | P02766 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | MAOB | P27338 | 1/20 | 0.41 |
| ▸ | NPBWR1 | P48145 | 1/20 | 0.41 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.41 |
| ▸ | HTR1A | P08908 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10444695 | 0.77 | NPC1 (0.55) | KMT2ASMN1; SMN2NPC1RAB9AKDM4E | |
| SCHEMBL7097532 | 0.76 | HTR1A (0.50) | ALDH1A1KMT2ASMN1; SMN2MAPTTTR | |
| SCHEMBL1126505 | 0.74 | KMT2A (0.67) | ALDH1A1KMT2AAKR1B1MAPTGAA | |
| SCHEMBL4579095 | 0.73 | KMT2A (0.66) | ALDH1A1KMT2ASMN1; SMN2NPC1MAPT | |
| SCHEMBL11607651 | 0.72 | ALDH1A1 (0.71) | ALDH1A1KMT2ASMN1; SMN2MAPTGAA | |
| SCHEMBL6365070 | 0.72 | HTR1A (0.52) | ALDH1A1MAPTTTRKDM4EHTR1A | |
| SCHEMBL11574390 | 0.72 | KMT2A (0.63) | ALDH1A1KMT2AAKR1B1SMN1; SMN2NPC1 | |
| SCHEMBL688071 | 0.71 | ALDH1A1 (0.70) | ALDH1A1KMT2AAKR1B1SMN1; SMN2NPC1 | |
| SCHEMBL11728624 | 0.71 | GPR35 (0.59) | ALDH1A1KMT2ASMN1; SMN2NPC1RAB9A | |
| SCHEMBL3857798 | 0.71 | SMN1; SMN2 (0.47) | ALDH1A1KMT2ASMN1; SMN2MAPTTTR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030114422-A1 | NOVEL QUINOXALINEDIONE DERIVATIVES, THEIR PREPARATION AND USE | NEUROSEARCH A/S (DK) | 2003-06-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030114422-A1 | NOVEL QUINOXALINEDIONE DERIVATIVES, THEIR PREPARATION AND USE | CHRNA3, CHRNA7, CHRNB3 | ALDH1A1 1501/4885KMT2A 2162/4885AKR1B1 265/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.